radoncreview_org
@radoncreview
Followers
4K
Following
1K
Media
159
Statuses
883
Our mission is to create the most comprehensively updated Rad Onc reference and to make it available for free, forever, for all.
Joined September 2019
Math checks out with absolute dose! HCC is a rather radiosensitive tumor. Interesting aside: A BED10 of >80 Gy with EBRT yields 80–90% local control. For context, 400 Gy in a single fraction equates to a BED10 of 16,400 Gy—yet the X-axis of this chart maxes out at 150 Gy. Of
0
10
26
RadOncReview ftw again. Thank you @jryckman3 🙏. Incredible resource. GI highlights below. #ASTRO25
Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇
3
22
75
The latest #ASTRO25 study dump now brings us to over 2,000 studies logged since May 2020. Happy studying and treating, and thank you for being part of this community! 🔗 https://t.co/NuyZMey8zx
Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇
0
2
1
Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇
docs.google.com
For best navigation, click on the table of contents to navigate and click on header or subheader to return to the table of contents. Otherwise, use the Document Outline feature (to the left on PC, or...
1
33
78
Here is a provocative paper for stage III. This data is suggestive of Rituximab + RT being curative treatment, with none of the 11 patients who received peri-radiation Rituximab experiencing relapse. DLBCL-free survival is a patient-centric endpoint! https://t.co/tZGR7K7ydD
0
2
3
Rituximab does not decrease transformation to DLBCL. Adding targeted, modern radiotherapy may decreases this ~20% long term risk by an order of magnitude. DLBCL-free survival is a meaningful endpoint for patients. Teamwork is key! 🤝 #LYMSM
https://t.co/FLUaKF0hYe
15-yr F/U of my fav study by Ardeshna et al.: W&W v Rx4 low tumor burden FL - median TTNT: NR in R maint, 14.8 yrs (!!!) in Rx4, 5.6 yrs in W&W - 34% of W&W cohort with no tx at 15 yrs! - women: shorter TTNT w/ W&W & longer TTNT with R maint (biological diff?) 1/2 #lymsm
1
5
4
Here is a provocative paper for stage III. This data is suggestive of Rituximab + RT being curative treatment, with none of the 11 patients who received peri-radiation Rituximab experiencing relapse. DLBCL-free survival is a patient-centric endpoint! https://t.co/tZGR7K7ydD
0
2
3
Rituximab does not decrease transformation to DLBCL. Adding targeted, modern radiotherapy may decreases this ~20% long term risk by an order of magnitude. DLBCL-free survival is a meaningful endpoint for patients. Teamwork is key! 🤝 #LYMSM
https://t.co/FLUaKF0hYe
15-yr F/U of my fav study by Ardeshna et al.: W&W v Rx4 low tumor burden FL - median TTNT: NR in R maint, 14.8 yrs (!!!) in Rx4, 5.6 yrs in W&W - 34% of W&W cohort with no tx at 15 yrs! - women: shorter TTNT w/ W&W & longer TTNT with R maint (biological diff?) 1/2 #lymsm
1
5
4
Seeing some logical fallacies in this debate. It not logically sound to assume that patients who progress on NAC-ICI wouldn’t have responded to upfront chemoradiotherapy.
@_ShankarSiva @FordePatrick @ElliotServaisMD @PercyLeeMD @biniamkidaneMD @BrendonStilesMD @DrewMoghanaki @RajaFlores @TimothyKruserMD @jdoningtonmd @gerryhanna @KHigginsMD @arbmckee @findlungcancer @bensolomon1 @peters_solange @TommyJohn00 @MOGA_ORG @JackWestMD @finn_corinne @DoctorJSpicer @DrJNaidoo @MARIANOPROVENCI Some intriguing data and personal reflections to contribute to this fantastic discussion. Around 10-20% of patients shuttled down NAC-ICI pathway didn’t proceed to resection or had R1+ margins highlight room for improvement. Many of these patients might have completed CCRT if
0
2
5
@NiuSanford @freddyeescorcia Also, radiotherapy can improve Child-Pugh scores from B ➡️ A. Lasley et al. Such a great paper! This fact tends to leave surgeons, IR, and med oncs equally jaw-dropped. Try dropping this fun fact at a GI tumor board near you! https://t.co/Z6uoXUCV5d
0
2
8
Math checks out with absolute dose! HCC is a rather radiosensitive tumor. Interesting aside: A BED10 of >80 Gy with EBRT yields 80–90% local control. For context, 400 Gy in a single fraction equates to a BED10 of 16,400 Gy—yet the X-axis of this chart maxes out at 150 Gy. Of
0
10
26
@NiuSanford @radoncreview @HCCLIVEConf I've never understood Y90 dosimetry. The prescription dose in Gy is so high, ~10x EBRT and ~3x LDR Brachy, despite Y90's half-life being much shorter than prostate LDR isotopes. Why does intravascular therapy require such a massive dose? Does any biologically relevant volume
0
2
6
Could ensuring a minimum dose to the entire tumor be just as, or even more, critical than ≥ 400 Gy in some areas, especially for larger tumors? Also, is there a way to prospectively guarantee full shoulder coverage, and is this coverage routinely quantified with Y-90? 🧩 #HCC
1
2
2
Is this the most important question? @HCCLIVEConf #HCC 🧩
Could ensuring a minimum dose to the entire tumor be just as, or even more, critical than ≥ 400 Gy in some areas, especially for larger tumors? Also, is there a way to prospectively guarantee full shoulder coverage, and is this coverage routinely quantified with Y-90? 🧩 #HCC
0
1
1
Until we get clear data - the story for larger tumors and especially MVI is that min dose does matter … I have seen tumor thrombus progress into confluence for example Until dosimetry is clear to interpret ( such as EYE90) along with positive phase 3 trial - onus is on y90
Could ensuring a minimum dose to the entire tumor be just as, or even more, critical than ≥ 400 Gy in some areas, especially for larger tumors? Also, is there a way to prospectively guarantee full shoulder coverage, and is this coverage routinely quantified with Y-90? 🧩 #HCC
1
2
12
Is this the most important question? @HCCLIVEConf #HCC 🧩
Could ensuring a minimum dose to the entire tumor be just as, or even more, critical than ≥ 400 Gy in some areas, especially for larger tumors? Also, is there a way to prospectively guarantee full shoulder coverage, and is this coverage routinely quantified with Y-90? 🧩 #HCC
0
1
1
0
1
8
@radoncreview @HCCLIVEConf Thanks Jeff, I think it highlights a good pt that Riad touches upon. Y90 and SBRT dose are measured differently though both in Gy...you don't need 400 Gy to whole tumor in HCC - it's a radiosensitive histology.
2
2
6
Could ensuring a minimum dose to the entire tumor be just as, or even more, critical than ≥ 400 Gy in some areas, especially for larger tumors? Also, is there a way to prospectively guarantee full shoulder coverage, and is this coverage routinely quantified with Y-90? 🧩 #HCC
1
2
2